Novartis, 2 Drug Cos. Strike Deal On Trileptal Patent
Two generics manufacturers have settled patent litigation over their abbreviated new drug applications for oxcarbazepine, the active ingredient in Swiss giant Novartis AG's popular anti-epileptic Trileptal, permitting both to sell tablets...To view the full article, register now.
Already a subscriber? Click here to view full article